Detail
Článek
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Metabolic profile of leukemia cells influences treatment efficacy of L-asparaginase

K. Hlozkova, A. Pecinova, N. Alquezar-Artieda, D. Pajuelo-Reguera, M. Simcikova, L. Hovorkova, K. Rejlova, M. Zaliova, T. Mracek, A. Kolenova, J. Stary, J. Trka, J. Starkova

. 2020 ; 20 (1) : 526. [pub] 20200605

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21012494

Grantová podpora
NV18-07-00129 Ministerstvo Zdravotnictví Ceské Republiky
16-12726S Grantová Agentura České Republiky

BACKGROUND: Effectiveness of L-asparaginase administration in acute lymphoblastic leukemia treatment is mirrored in the overall outcome of patients. Generally, leukemia patients differ in their sensitivity to L-asparaginase; however, the mechanism underlying their inter-individual differences is still not fully understood. We have previously shown that L-asparaginase rewires the biosynthetic and bioenergetic pathways of leukemia cells to activate both anti-leukemic and pro-survival processes. Herein, we investigated the relationship between the metabolic profile of leukemia cells and their sensitivity to currently used cytostatic drugs. METHODS: Altogether, 19 leukemia cell lines, primary leukemia cells from 26 patients and 2 healthy controls were used. Glycolytic function and mitochondrial respiration were measured using Seahorse Bioanalyzer. Sensitivity to cytostatics was measured using MTS assay and/or absolute count and flow cytometry. Mitochondrial membrane potential was determined as TMRE fluorescence. RESULTS: Using cell lines and primary patient samples we characterized the basal metabolic state of cells derived from different leukemia subtypes and assessed their sensitivity to cytostatic drugs. We found that leukemia cells cluster into distinct groups according to their metabolic profile. Lymphoid leukemia cell lines and patients sensitive to L-asparaginase clustered into the low glycolytic cluster. While lymphoid leukemia cells with lower sensitivity to L-asparaginase together with resistant normal mononuclear blood cells gathered into the high glycolytic cluster. Furthermore, we observed a correlation of specific metabolic parameters with the sensitivity to L-asparaginase. Greater ATP-linked respiration and lower basal mitochondrial membrane potential in cells significantly correlated with higher sensitivity to L-asparaginase. No such correlation was found in the other cytostatic drugs tested by us. CONCLUSIONS: These data support that cell metabolism plays a prominent role in the treatment effect of L-asparaginase. Based on these findings, leukemia patients with lower sensitivity to L-asparaginase with no specific genetic characterization could be identified by their metabolic profile.

000      
00000naa a2200000 a 4500
001      
bmc21012494
003      
CZ-PrNML
005      
20210507101746.0
007      
ta
008      
210420s2020 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s12885-020-07020-y $2 doi
035    __
$a (PubMed)32503472
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Hlozkova, Katerina $u CLIP - Childhood Leukaemia Investigation Prague, Prague, Czech Republic $u Department of Pediatric Hematology and Oncology, Second Faculty of Medicine, Charles University, Prague, Czech Republic
245    10
$a Metabolic profile of leukemia cells influences treatment efficacy of L-asparaginase / $c K. Hlozkova, A. Pecinova, N. Alquezar-Artieda, D. Pajuelo-Reguera, M. Simcikova, L. Hovorkova, K. Rejlova, M. Zaliova, T. Mracek, A. Kolenova, J. Stary, J. Trka, J. Starkova
520    9_
$a BACKGROUND: Effectiveness of L-asparaginase administration in acute lymphoblastic leukemia treatment is mirrored in the overall outcome of patients. Generally, leukemia patients differ in their sensitivity to L-asparaginase; however, the mechanism underlying their inter-individual differences is still not fully understood. We have previously shown that L-asparaginase rewires the biosynthetic and bioenergetic pathways of leukemia cells to activate both anti-leukemic and pro-survival processes. Herein, we investigated the relationship between the metabolic profile of leukemia cells and their sensitivity to currently used cytostatic drugs. METHODS: Altogether, 19 leukemia cell lines, primary leukemia cells from 26 patients and 2 healthy controls were used. Glycolytic function and mitochondrial respiration were measured using Seahorse Bioanalyzer. Sensitivity to cytostatics was measured using MTS assay and/or absolute count and flow cytometry. Mitochondrial membrane potential was determined as TMRE fluorescence. RESULTS: Using cell lines and primary patient samples we characterized the basal metabolic state of cells derived from different leukemia subtypes and assessed their sensitivity to cytostatic drugs. We found that leukemia cells cluster into distinct groups according to their metabolic profile. Lymphoid leukemia cell lines and patients sensitive to L-asparaginase clustered into the low glycolytic cluster. While lymphoid leukemia cells with lower sensitivity to L-asparaginase together with resistant normal mononuclear blood cells gathered into the high glycolytic cluster. Furthermore, we observed a correlation of specific metabolic parameters with the sensitivity to L-asparaginase. Greater ATP-linked respiration and lower basal mitochondrial membrane potential in cells significantly correlated with higher sensitivity to L-asparaginase. No such correlation was found in the other cytostatic drugs tested by us. CONCLUSIONS: These data support that cell metabolism plays a prominent role in the treatment effect of L-asparaginase. Based on these findings, leukemia patients with lower sensitivity to L-asparaginase with no specific genetic characterization could be identified by their metabolic profile.
650    _2
$a mladiství $7 D000293
650    _2
$a antitumorózní látky $x farmakologie $x terapeutické užití $7 D000970
650    _2
$a asparaginasa $x farmakologie $x terapeutické užití $7 D001215
650    _2
$a biosyntetické dráhy $x účinky léků $7 D053898
650    _2
$a kostní dřeň $x patologie $7 D001853
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a dítě $7 D002648
650    _2
$a předškolní dítě $7 D002675
650    _2
$a chemorezistence $7 D019008
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a glykolýza $x účinky léků $7 D006019
650    _2
$a lidé $7 D006801
650    _2
$a kojenec $7 D007223
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a membránový potenciál mitochondrií $x účinky léků $7 D053078
650    _2
$a metabolom $x účinky léků $7 D055442
650    _2
$a mitochondrie $x účinky léků $x metabolismus $7 D008928
650    _2
$a oxidativní fosforylace $x účinky léků $7 D010085
650    _2
$a akutní lymfatická leukemie $x krev $x farmakoterapie $x patologie $7 D054198
650    _2
$a výsledek terapie $7 D016896
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
700    1_
$a Pecinova, Alena $u Department of Bioenergetics, Institute of Physiology of the Czech Academy of Sciences, Prague, Czech Republic
700    1_
$a Alquezar-Artieda, Natividad $u CLIP - Childhood Leukaemia Investigation Prague, Prague, Czech Republic $u Department of Pediatric Hematology and Oncology, Second Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Pajuelo-Reguera, David $u CLIP - Childhood Leukaemia Investigation Prague, Prague, Czech Republic $u Department of Pediatric Hematology and Oncology, Second Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Simcikova, Marketa $u CLIP - Childhood Leukaemia Investigation Prague, Prague, Czech Republic $u Department of Pediatric Hematology and Oncology, Second Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Hovorkova, Lenka $u CLIP - Childhood Leukaemia Investigation Prague, Prague, Czech Republic $u Department of Pediatric Hematology and Oncology, Second Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Rejlova, Katerina $u CLIP - Childhood Leukaemia Investigation Prague, Prague, Czech Republic $u Department of Pediatric Hematology and Oncology, Second Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Zaliova, Marketa $u CLIP - Childhood Leukaemia Investigation Prague, Prague, Czech Republic $u Department of Pediatric Hematology and Oncology, Second Faculty of Medicine, Charles University, Prague, Czech Republic $u University Hospital Motol, Prague, Czech Republic
700    1_
$a Mracek, Tomas $u Department of Bioenergetics, Institute of Physiology of the Czech Academy of Sciences, Prague, Czech Republic
700    1_
$a Kolenova, Alexandra $u Department of Pediatric Hematology and Oncology, National Institute of Children's Diseases and Medical Faculty, Comenius University, Bratislava, Slovakia
700    1_
$a Stary, Jan $u Department of Pediatric Hematology and Oncology, Second Faculty of Medicine, Charles University, Prague, Czech Republic $u University Hospital Motol, Prague, Czech Republic
700    1_
$a Trka, Jan $u CLIP - Childhood Leukaemia Investigation Prague, Prague, Czech Republic $u Department of Pediatric Hematology and Oncology, Second Faculty of Medicine, Charles University, Prague, Czech Republic $u University Hospital Motol, Prague, Czech Republic
700    1_
$a Starkova, Julia $u CLIP - Childhood Leukaemia Investigation Prague, Prague, Czech Republic. julia.starkova@lfmotol.cuni.cz $u Department of Pediatric Hematology and Oncology, Second Faculty of Medicine, Charles University, Prague, Czech Republic. julia.starkova@lfmotol.cuni.cz
773    0_
$w MED00008171 $t BMC cancer $x 1471-2407 $g Roč. 20, č. 1 (2020), s. 526
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32503472 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210420 $b ABA008
991    __
$a 20210507101745 $b ABA008
999    __
$a ok $b bmc $g 1650789 $s 1132873
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 20 $c 1 $d 526 $e 20200605 $i 1471-2407 $m BMC cancer $n BMC Cancer $x MED00008171
GRA    __
$a NV18-07-00129 $p Ministerstvo Zdravotnictví Ceské Republiky
GRA    __
$a 16-12726S $p Grantová Agentura České Republiky
LZP    __
$a Pubmed-20210420

Najít záznam

Citační ukazatele

Nahrávání dat...

Možnosti archivace

Nahrávání dat...